Febuxostat belongs to the therapeutic drugs for hyperuricemia and should not be used for the treatment of fatty liver, which will not be aggravated during use. Febuxostat is a xanthine oxidase (XO) inhibitor and is indicated for the long-term treatment of hyperuricemia with gout symptoms, but it is not recommended for the treatment of asymptomatic hyperuricemia. Long-term consumption of febuxostat does not aggravate fatty liver. However, its long-term use can cause abnormalities in liver metabolism with mild symptoms, no special adjustment of dosing is needed for patients with mild and moderate liver function abnormalities, and dosing can be adjusted for patients with severe liver function abnormalities, liver function needs to be monitored during dosing, and dosing needs to be discontinued when the value of aminotransferases exceeds three times the normal value. The drug has nausea, arthralgia, skin rash and other adverse reactions, the emergence of built fatty liver is recommended to consult a doctor in a timely manner, under the guidance of the doctor to use the drug, do not use the drug on their own, so as not to cause adverse reactions.